Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s): MYCOF

Healthcare Advertising Agencies

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

CSE:MYCO - Post by User

Mydecine Innovations Group Inc

Bullboard Posts

Comment by SSM0006on Dec 22, 2017 10:34am

23 Views

Post# 27214824

RE:News out on SEDAR

I think that this is great news! Trying to go through different strains and matching terpenes for particular medical reasons is difficult, time consuming and in the end, did we get it right?
For medical users, me as one, this will help navigate the terpenes that are not necessarily all listed when we buy a product.

It's nice to see that NF is taking this initiative.

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario